On February 5, 2015, Koizumi, Noriko; Okumura, Naoki; Kinoshita, Shigeru published a patent.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one The title of the patent was Drug for prevention or treatment of diseases associated with abnormalities in extracellular matrix (ECM) of corneal endothelium. And the patent contained the following:
The drug, especially for diseases associated with Fuchs’ corneal endothelial dystrophy. contains a TGF-β signal inhibitor. Also claimed are the TGF-β signal inhibitor for the drug, and the treatment/prevention method by administration of the TGF-β inhibitor. Such diseases include photophobia, blurred vision, vision disorders, eye pain, tearing, hyperemia, pain, bullous keratopathy, eye discomfort, contrast reduction, glare, edema of the corneal stroma, bullous keratopathy and corneal opacity. The TGF β-signal inhibitor may be 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide. The experimental process involved the reaction of 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one(cas: 1009104-85-1).Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one
The Article related to tgf signal inhibitor corneal endothelial ecm disease fuchs dystrophy, Pharmaceuticals: Formulation and Compounding and other aspects.Recommanded Product: 1-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one
Referemce:
Isoquinoline – Wikipedia,
Isoquinoline | C9H7N – PubChem